NCT07523464Not yet recruitingPhase 1
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
A Single-Arm Phase I Clinical Study of Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This is a single-center, prospective, open-label, single-arm phase I exploratory study designed to evaluate the safety and feasibility of a novel central immune-priming radiotherapy strategy in patients with unresectable stage III non-small cell lung cancer (NSCLC). The investigational approach consists of a single 8 Gy/1 fraction radiotherapy dose delivered to the central subregion of the primary tumor, with rapid dose fall-off to keep the peripheral tumor margin dose below 4 Gy, followed by one cycle of PD-(L)1 inhibitor, and then standard concurrent chemoradiotherapy (cCRT) approximately one week later. Patients without disease progression after cCRT will subsequently receive consolidation immune checkpoint inhibitor therapy. The primary objective is to assess the safety and feasibility of this lead-in immune-priming strategy, particularly whether it can be integrated into standard cCRT and subsequent immunotherapy without unacceptable toxicity or treatment delay. The primary endpoint is the dose-limiting toxicity (DLT) rate, with the DLT observation window defined from initiation of the priming radiotherapy to 6-8 weeks after completion of cCRT. Secondary objectives include the on-time initiation rate of cCRT, cCRT completion rate, initiation rate of consolidation immunotherapy, acute and subacute toxicity profile, preliminary efficacy signals, and dynamic changes in peripheral lymphocyte counts. Exploratory analyses will investigate peripheral immune cell subsets, circulating tumor DNA (ctDNA), T-cell receptor (TCR) clonality, cytokine changes, and their associations with toxicity and clinical outcomes. The study will adopt a safety run-in plus expansion design, with an initial cohort of 6 patients and expansion to 24 patients if safety is acceptable.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 5 Apr 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07523464
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- From 1 Jun 2026 to the primary completion date, 30 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior definitive thoracic radiotherapy or prior systemic antitumor treatment for the current disease;
- Active interstitial lung disease, prior severe radiation pneumonitis, or immune-related pneumonitis;
- Special primary tumor location such that safety constraints for centrally confined priming radiotherapy cannot be met;
Other illness
- Active autoimmune disease or need for long-term systemic immunosuppressive therapy;
- Any other condition that, in the opinion of the investigator, makes the patient unsuitable for this study.
Other
- Presence of distant metastasis;
- Positive driver gene alterations;
- Primary lesion immediately adjacent to the main bronchus, carina, major vessels, or esophagus, such that the investigator judges the lead-in intervention to be excessively risky;
- Pregnancy or lactation;
Who the study is looking for
- Age 18 to 75 years;
- Histologically or cytologically confirmed NSCLC;
- Unresectable stage III disease according to the AJCC 8th edition;
- Negative for driver gene alterations;
- Considered suitable for definitive cCRT by MDT discussion or investigator judgment;
- ECOG performance status 0-1;
- Presence of a clearly delineable pulmonary primary lesion allowing centrally confined priming treatment planning;
- Adequate major organ function as required by the study;
- Willingness to participate and provision of written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.